Cancer Research Cancer Research Funding Available  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, L.-C.
Right arrow Articles by Dahiya, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L.-C.
Right arrow Articles by Dahiya, R.
[Cancer Research 60, 702-706, February 1, 2000]
© 2000 American Association for Cancer Research


Regular Articles

Frequent Methylation of Estrogen Receptor in Prostate Cancer: Correlation with Tumor Progression1

Long-Cheng Li, Richard Chui, Koichi Nakajima, Bong Ryoul Oh, Harry C. Au and Rajvir Dahiya2

Department of Urology, Veterans Affairs Medical Center, and University of California–San Francisco, San Francisco, California 94121

Prior studies have shown that the estrogen receptor (ER) gene is down-regulated in prostate cancer, but the mechanism of its inactivation is not known. We hypothesize that inactivation of the ER gene in prostate cancer is through promoter methylation. To test this hypothesis, we investigated the methylation status of the ER gene in prostate cancer cell lines, prostate cancer, and benign prostatic hyperplasia (BPH) tissues samples using the bisulfite genomic sequencing method. Our results show that the ER gene promoter was methylated in 100% (six of six) of the prostate cancer cell lines tested and all were accompanied by loss of ER mRNA expression. Treatment of these cell lines with demethylating agent 5-aza-2'-deoxycytidine restored ER mRNA expression in all of the ER-negative cell lines. In addition, elevated expression of DNA methyltransferase mRNA was found in all of the prostate cancer cell lines. Of the prostate tissue samples analyzed, 60% (6 of 10) in the BPH samples, 80% (8 of 10) in the low-grade cancer samples (grades I and II), and 95% (20 of 21) in the high-grade cancer samples (grades III-V) exhibited promoter methylation of the ER gene. The overall methylation levels in the cancer samples were higher than that in the BPH samples. The differences between the high-grade cancer samples and BPH samples were significant at all CpG sites. Only at three CpG sites were the differences significant between the low-grade cancer samples and BPH samples. This study presents the first evidence that ER gene is transcriptionally inactivated by DNA methylation in prostate cancer. Our data suggest that ER may be involved in the pathogenesis of prostate cancer, as well as BPH.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
M. Chen, J. Ni, H.-C. Chang, C.-Y. Lin, M. Muyan, and S. Yeh
CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells
Carcinogenesis, May 1, 2009; 30(5): 841 - 850.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
H. Asada, Y. Yamagata, T. Taketani, A. Matsuoka, H. Tamura, N. Hattori, J. Ohgane, N. Hattori, K. Shiota, and N. Sugino
Potential link between estrogen receptor-{alpha} gene hypomethylation and uterine fibroid formation
Mol. Hum. Reprod., September 1, 2008; 14(9): 539 - 545.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. C. Baker Jr., J. H. Ostrander, S. Lem, G. Broadwater, G. R. Bean, N. C. D'Amato, V. K. Goldenberg, C. Rowell, C. Ibarra-Drendall, T. Grant, et al.
ESR1 Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention
Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 1884 - 1890.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. Y. Park, H. Sakamoto, S. D. Kirley, S. Ogino, T. Kawasaki, E. Kwon, M. Mino-Kenudson, G. Y. Lauwers, D. C. Chung, B. R. Rueda, et al.
The Cables Gene on Chromosome 18q Is Silenced by Promoter Hypermethylation and Allelic Loss in Human Colorectal Cancer
Am. J. Pathol., November 1, 2007; 171(5): 1509 - 1519.
[Abstract] [Full Text] [PDF]


Home page
INT J SURG PATHOLHome page
Y.-F. Zhao, Y.-G. Zhang, X.-X. Tian, Juan Du, and Jie Zheng
Aberrant Methylation of Multiple Genes in Gastric Carcinomas
International Journal of Surgical Pathology, July 1, 2007; 15(3): 242 - 251.
[Abstract] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L.-C. Li, S. T. Okino, H. Zhao, D. Pookot, R. F. Place, S. Urakami, H. Enokida, and R. Dahiya
Small dsRNAs induce transcriptional activation in human cells
PNAS, November 14, 2006; 103(46): 17337 - 17342.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. S Perry, R. Foley, K. Woodson, and M. Lawler
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-M. Ho, W.-Y. Tang, J. Belmonte de Frausto, and G. S. Prins
Developmental Exposure to Estradiol and Bisphenol A Increases Susceptibility to Prostate Carcinogenesis and Epigenetically Regulates Phosphodiesterase Type 4 Variant 4
Cancer Res., June 1, 2006; 66(11): 5624 - 5632.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. M. Das and R. Singal
DNA Methylation and Cancer
J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci
The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation
Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Sasaki, M. Kaneuchi, N. Sakuragi, and R. Dahiya
Multiple Promoters of Catechol-O-methyltransferase Gene Are Selectively Inactivated by CpG Hypermethylation in Endometrial Cancer
Cancer Res., June 15, 2003; 63(12): 3101 - 3106.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Sasaki, Y. Tanaka, G. Perinchery, A. Dharia, I. Kotcherguina, S. i. Fujimoto, and R. Dahiya
Methylation and Inactivation of Estrogen, Progesterone, and Androgen Receptors in Prostate Cancer
J Natl Cancer Inst, March 6, 2002; 94(5): 384 - 390.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. R Dimitrova, K. DeGroot, A. K Myers, and Y. D Kim
Estrogen and homocysteine
Cardiovasc Res, February 15, 2002; 53(3): 577 - 588.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. F. Schmitt, D. S. Millar, J. S. Pedersen, S. L. Clark, D. J. Venter, M. Frydenberg, P. L. Molloy, and G. P. Risbridger
Hypermethylation of the Inhibin {alpha}-Subunit Gene in Prostate Carcinoma
Mol. Endocrinol., February 1, 2002; 16(2): 213 - 220.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Pasquali, V. Rossi, D. Esposito, C. Abbondanza, G. A. Puca, A. Bellastella, and A. A. Sinisi
Loss of Estrogen Receptor {beta} Expression in Malignant Human Prostate Cells in Primary Cultures and in Prostate Cancer Tissues
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2051 - 2055.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. Sasaki, L. Kotcherguina, A. Dharia, S. Fujimoto, and R. Dahiya
Cytosine-Phosphoguanine Methylation of Estrogen Receptors in Endometrial Cancer
Cancer Res., April 1, 2001; 61(8): 3262 - 3266.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
A. Latil, I. Bièche, D. Vidaud, R. Lidereau, P. Berthon, O. Cussenot, and M. Vidaud
Evaluation of Androgen, Estrogen (ER{{alpha}} and ER{beta}), and Progesterone Receptor Expression in Human Prostate Cancer by Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction Assays
Cancer Res., March 1, 2001; 61(5): 1919 - 1926.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. Sasaki, A. Dharia, B. R. Oh, Y. Tanaka, S.-i. Fujimoto, and R. Dahiya
Progesterone Receptor B Gene Inactivation and CpG Hypermethylation in Human Uterine Endometrial Cancer
Cancer Res., January 1, 2001; 61(1): 97 - 102.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
C. I. Truica, S. Byers, and E. P. Gelmann
{beta}-Catenin Affects Androgen Receptor Transcriptional Activity and Ligand Specificity
Cancer Res., September 1, 2000; 60(17): 4709 - 4713.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.